New trial matches liver cancer treatment to Tumor's Fat-Burning signature

This phase II trial tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will classify each patient's tumor by its fatty acid degradation (FAD) subtype and assign either a drug combination (camrelizumab plus apatinib) or the same drugs plus a liver-directed procedure (TACE). The goal is to see if matching treatment to tumor metabolism improves response rates. The study plans to enroll 86 adults with unresectable hepatocellular carcinoma who have not had prior systemic therapy.